3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
20
Leukemia, Myeloid, Chronic-Phase
7
Leukemia, Myeloid
3
Leukemia
3
Bronchiolitis Obliterans Syndrome
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Philadelphia Chromosome
2
Myeloproliferative Disorders
2
Recurrence
1
P1b: Advanced Solid Tumors
1
Malignant Solid Tumors
1
Hematologic Diseases
1
HER2+ Metastatic Breast Cancer
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Blast Crisis
1
Advanced Solid Tumors
1
Interventions
Cyclophosphamide
64
Peripheral Blood Stem Cell Transplantation
57
fludarabine phosphate
54
Busulfan
43
Tacrolimus
38
Methotrexate
38
Cytarabine
36
Filgrastim
34
Cyclosporine
33
Mycophenolic Acid
32
Antilymphocyte Serum
32
Whole-Body Irradiation
27
Radiotherapy
25
Methylprednisolone
22
Imatinib Mesylate
22
Etoposide
22
Melphalan
18
Cord Blood Stem Cell Transplantation
17
Thiotepa
12
Dasatinib
12
Flow Cytometry
11
sargramostim
10
merphos
10
fludarabine
10
Sirolimus
10
Granulocyte Colony-Stimulating Factor
10
Therapeutics
9
Prednisone
9
Decitabine
9
Carboplatin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Blast Crisis
×
asciminib
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled